Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO plc has announced that its hLAB division has secured a £3.2 million contract to provide virology and immunology lab services for a US biotechnology client’s Phase 2 influenza drug study. This contract is the largest standalone lab contract in the company’s history, reflecting its enhanced lab capacity and strategic growth plan following the move to a new facility at Canary Wharf. The project is expected to generate significant revenue in 2025 and 2026, highlighting hVIVO’s commitment to optimizing and diversifying their service offerings.
More about Open Orphan Plc
hVIVO plc is a rapidly expanding contract research organization specializing in infectious and respiratory disease products. They are recognized as global leaders in human challenge clinical trials and offer comprehensive early-stage clinical development services. Their services include an array of human challenge models, drug development consultancy, and laboratory services through their hLAB brand, focusing on virology and immunology testing.
YTD Price Performance: -11.71%
Average Trading Volume: 3,119,371
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £123.1M
For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.
